Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Lupus Nephritis Treatment Pipeline Review H2 2016

Monday, October 31, 2016 0:16
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Lupus Nephritis – Pipeline Review, H2 2016’, provides an overview of the Lupus Nephritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lupus Nephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lupus Nephritis and features dormant and discontinued projects.

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

 

Request a sample report @ https://www.wiseguyreports.com/sample-request/711814-lupus-nephritis-pipeline-review-h2-2016

 

Scope

- The report provides a snapshot of the global therapeutic landscape of Lupus Nephritis
- The report reviews pipeline therapeutics for Lupus Nephritis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Lupus Nephritis therapeutics and enlists all their major and minor projects
- The report assesses Lupus Nephritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Lupus Nephritis

 

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Lupus Nephritis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lupus Nephritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Complete report details @ https://www.wiseguyreports.com/reports/711814-lupus-nephritis-pipeline-review-h2-2016

 

 

 

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Report Coverage 8
Lupus Nephritis Overview 9
Therapeutics Development 10
Pipeline Products for Lupus Nephritis – Overview 10
Pipeline Products for Lupus Nephritis – Comparative Analysis 11
Lupus Nephritis – Therapeutics under Development by Companies 12
Lupus Nephritis – Therapeutics under Investigation by Universities/Institutes 14
Lupus Nephritis – Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Lupus Nephritis – Products under Development by Companies 18
Lupus Nephritis – Products under Investigation by Universities/Institutes 20
Lupus Nephritis – Companies Involved in Therapeutics Development 21
AbbVie Inc 21
Asahi Kasei Pharma Corp. 22
Astellas Pharma Inc. 23
Aurinia Pharmaceuticals Inc 24
Azano Pharmaceuticals Inc. 25
Boehringer Ingelheim GmbH 26
Bristol-Myers Squibb Company 27
Deltanoid Pharmaceuticals Inc. 28
F. Hoffmann-La Roche Ltd. 29
GlaxoSmithKline Plc 30
HanAll Biopharma Co., Ltd. 31
Invion Limited 32
KPI Therapeutics, Inc. 33
MedImmune, LLC 34
Omeros Corporation 35
Ra Pharmaceuticals, Inc. 36
Resolve Therapeutics, LLC 37
Takeda Pharmaceutical Company Limited 38
TxCell SA 39
Lupus Nephritis – Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Target 41
Assessment by Mechanism of Action 43
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
abatacept – Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
anifrolumab – Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
belimumab – Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
BI-655064 – Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
BMS-986147 – Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
dalazatide – Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
DP-001 – Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Drug to Antagonize Bradykinin Receptor B1 for Lupus Nephritis – Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
ENTX-DN – Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
HL-161 – Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
INV-103 – Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
ixazomib citrate – Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
mizoribine – Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
Monoclonal Antibody for Lupus Nephritis – Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
obinutuzumab – Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
OMS-721 – Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
P-Dex – Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
RA-101495 – Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
RO-5461111 – Drug Profile 102
Product Description 102
Mechanism Of Action 102
R&D Progress 102
RSLV-145 – Drug Profile 103
Product Description 103
Mechanism Of Action 103
R&D Progress 103
Stem Cell Therapy for Autoimmune Diseases – Drug Profile 104
Product Description 104
Mechanism Of Action 104
R&D Progress 104
Synthetic Peptide to Inhibit Complement C5 for Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome and Autoimmune Disorders – Drug Profile 106
Product Description 106
Mechanism Of Action 106
R&D Progress 106
venetoclax – Drug Profile 107
Product Description 107
Mechanism Of Action 107
R&D Progress 107
voclosporin – Drug Profile 116
Product Description 116
Mechanism Of Action 116
R&D Progress 116
Y-175L – Drug Profile 123
Product Description 123
Mechanism Of Action 123
R&D Progress 123
Lupus Nephritis – Dormant Projects 124
Lupus Nephritis – Discontinued Products 126
Lupus Nephritis – Product Development Milestones 127
Featured News & Press Releases 127
Aug 15, 2016: Aurinia Pharmaceuticals Announces Voclosporin Meets Primary Endpoint in Phase IIB AURA-LV Study in Lupus Nephritis 127
Jun 28, 2016: Aurinia Announces 24 Week Remission Rates from the First Seven Patients in its Open Label AURION Study in Lupus Nephritis (LN) 129
Jun 10, 2016: Alliance for Children Therapeutics Presents Dalazatide Data Demonstrating Positive Response in Lupus 130
May 23, 2016: KPI Therapeutics to Present Updated Dalazatide Study Data in Lupus 131
May 12, 2016: Aurinia Announces Presentations at the European Renal Association – European Dialysis and Transplant Association Meeting 131
May 09, 2016: Aurinia Initiates First Clinical Study of Voclosporin for Japan 132
Apr 20, 2016: Patient Dosing Initiated for OMS721 Phase 2 Program in Renal Diseases 133
Mar 29, 2016: Aurinia Announces Result from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis – Study to Continue as Planned 134
Mar 02, 2016: Aurina Receives FDA Fast Track Designation for Voclosporin for the Treatment of Lupus Nephritis 135
Feb 08, 2016: Aurinia Announces Preliminary Topline Data From its Open Label Aurion Study in Lupus Nephritis 135
Feb 02, 2016: Deltanoid Pharmaceuticals Announces Appointment of Douglas Jermasek as Chief Executive Officer 136
Jan 19, 2016: Aurinia Announces Completion of Patient Enrollment in Its Phase 2B AURA-LV Study in Lupus Nephritis 137
Dec 03, 2015: Ocata’s Hemangio-derived Mesenchymal Cells Preserve Kidney Function and Extend Lifespan in Preclinical Model of Lupus Nephritis 138
Nov 24, 2015: Aurinia Pharmaceuticals Announces Outcome from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis – Study to Continue as Planned 139
Nov 10, 2015: Kineta, Seattle Children’s Research Institute Present New Data Demonstrating Positive, Predictive Responses to Dalazatide In Lupus 139
Appendix 141
Methodology 141
Coverage 141
Secondary Research 141
Primary Research 141
Expert Panel Validation 141
Contact Us 141
Disclaimer 142

 

Get It now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=711814

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)        

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.